Recent Data from BESPOKE-CRC

Opinion
Video

Colorectal cancer specialists review recent updates from BESPOKE-CRC evaluating the utilization of circulating tumor DNA for informing adjuvant therapy in patients with colorectal cancer.

CN_BTL_CRC_Seg06_BESPOKE
Current Time 0:00
Duration 3:58
Loaded: 0%
Stream Type LIVE
Remaining Time 3:58
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Recent Videos
    KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025
    KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025
    IO-IO vs IO-TKI: Expert Approaches to First-Line RCC Treatment Selection
    IO-IO vs IO-TKI: Expert Approaches to First-Line RCC Treatment Selection
    Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
    Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
    Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC
    Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC
    From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses
    From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses
    From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum
    From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum
    Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC
    Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC
    CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC
    CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC
    3 experts in this video
    Key Takeaways and Future in Advanced Gastric Cancer Treatment
    3 experts in this video
    Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers
    Related Content
    HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

    HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

    Tim Cortese
    March 31st 2025
    Article

    Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

    The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

    Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

    Marwan G. Fakih, MD
    February 24th 2025
    Podcast

    The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

    Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

    Sirexatamab Combo Shows Positive Activity in Advanced MSS Colorectal Cancer

    Russ Conroy
    March 31st 2025
    Article

    Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

    Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

    Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

    Jagoda Misniakiewicz, PharmD
    June 10th 2024
    Podcast

    Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

    In a small cohort of patients with MMS/pMMR CRC, the suvemcitug and envafolimab pharmacokinetic profiles were comparable with prior monotherapy studies.

    Suvemcitug Combination Therapy Exhibits Safety, Activity in MSS/pMMR CRC

    Roman Fabbricatore
    March 2nd 2025
    Article

    In a small cohort of patients with MMS/pMMR CRC, the suvemcitug and envafolimab pharmacokinetic profiles were comparable with prior monotherapy studies.

    Phase 3 CheckMate-8HW trial results evaluating the combination in microsatellite instability–high or mismatch repair deficient CRC supported the decision.

    FDA Grants Priority Review to Nivolumab/Ipilimumab in MSI-H/dMMR CRC

    Roman Fabbricatore
    February 24th 2025
    Article

    Phase 3 CheckMate-8HW trial results evaluating the combination in microsatellite instability–high or mismatch repair deficient CRC supported the decision.